Clinical Trials Logo

Plasma Cell Myeloma Refractory clinical trials

View clinical trials related to Plasma Cell Myeloma Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT06356571 Not yet recruiting - Clinical trials for Plasma Cell Myeloma Refractory

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

SubQSA
Start date: June 11, 2024
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

NCT ID: NCT04643002 Recruiting - Clinical trials for Plasma Cell Myeloma Refractory

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Start date: January 25, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.